AN2 Therapeutics, Inc. (ANTX) Misses Q4 EPS by 7c

AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported Q4 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22).

For earnings history and earnings-related data on AN2 Therapeutics, Inc. (ANTX) click here.

You May Also Be Interested In

• Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
• After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
• Snowflake (SNOW) Tops Q2 EPS by 17c, Offers Guidance